BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

364 related articles for article (PubMed ID: 29161904)

  • 1. Consequences of testing for mismatch repair deficiency of colorectal cancer in clinical practice.
    Leicher LW; Lammertink MHA; Offerman SR; Morreau H; de Jong MM; de Groot JWB; van Westreenen HL; Vasen HFA; de Vos Tot Nederveen Cappel WH
    Scand J Gastroenterol; 2018 May; 53(5):632-636. PubMed ID: 29161904
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and molecular characterisation of hereditary and sporadic metastatic colorectal cancers harbouring microsatellite instability/DNA mismatch repair deficiency.
    Cohen R; Buhard O; Cervera P; Hain E; Dumont S; Bardier A; Bachet JB; Gornet JM; Lopez-Trabada D; Dumont S; Kaci R; Bertheau P; Renaud F; Bibeau F; Parc Y; Vernerey D; Duval A; Svrcek M; André T
    Eur J Cancer; 2017 Nov; 86():266-274. PubMed ID: 29055842
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DNA mismatch repair deficiency and hereditary syndromes in Latino patients with colorectal cancer.
    Ricker CN; Hanna DL; Peng C; Nguyen NT; Stern MC; Schmit SL; Idos GE; Patel R; Tsai S; Ramirez V; Lin S; Shamasunadara V; Barzi A; Lenz HJ; Figueiredo JC
    Cancer; 2017 Oct; 123(19):3732-3743. PubMed ID: 28640387
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of yield and experiences of age-related molecular investigation for heritable and nonheritable causes of mismatch repair deficient colorectal cancer to identify Lynch syndrome.
    Vos JR; Fakkert IE; Spruijt L; Willems RW; Langenveld S; Mensenkamp AR; Leter EM; Nagtegaal ID; Ligtenberg MJL; Hoogerbrugge N;
    Int J Cancer; 2020 Oct; 147(8):2150-2158. PubMed ID: 32510614
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Colorectal cancer due to deficiency in DNA mismatch repair function: a review.
    Bellizzi AM; Frankel WL
    Adv Anat Pathol; 2009 Nov; 16(6):405-17. PubMed ID: 19851131
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor testing to identify lynch syndrome in two Australian colorectal cancer cohorts.
    Buchanan DD; Clendenning M; Rosty C; Eriksen SV; Walsh MD; Walters RJ; Thibodeau SN; Stewart J; Preston S; Win AK; Flander L; Ouakrim DA; Macrae FA; Boussioutas A; Winship IM; Giles GG; Hopper JL; Southey MC; English D; Jenkins MA
    J Gastroenterol Hepatol; 2017 Feb; 32(2):427-438. PubMed ID: 27273229
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PREMM5 distinguishes sporadic from Lynch syndrome-associated MMR-deficient/MSI-high colorectal cancer.
    Sandoval RL; Horiguchi M; Ukaegbu C; Furniss CS; Uno H; Syngal S; Yurgelun MB
    Fam Cancer; 2023 Oct; 22(4):459-465. PubMed ID: 37572151
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Microsatellite instability testing and its role in the management of colorectal cancer.
    Kawakami H; Zaanan A; Sinicrope FA
    Curr Treat Options Oncol; 2015 Jul; 16(7):30. PubMed ID: 26031544
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DNA mismatch repair deficiency in sporadic colorectal cancer and Lynch syndrome.
    Poulogiannis G; Frayling IM; Arends MJ
    Histopathology; 2010 Jan; 56(2):167-79. PubMed ID: 20102395
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lynch syndrome and Lynch syndrome mimics: The growing complex landscape of hereditary colon cancer.
    Carethers JM; Stoffel EM
    World J Gastroenterol; 2015 Aug; 21(31):9253-61. PubMed ID: 26309352
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular testing for Lynch syndrome in people with colorectal cancer: systematic reviews and economic evaluation.
    Snowsill T; Coelho H; Huxley N; Jones-Hughes T; Briscoe S; Frayling IM; Hyde C
    Health Technol Assess; 2017 Sep; 21(51):1-238. PubMed ID: 28895526
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A practical screening strategy for Lynch syndrome and Lynch syndrome mimics in colorectal cancer.
    Yao ZG; Lv BB; Jing HY; Su WJ; Li JM; Fan H; Zhao MQ; Qin YJ; Sun XC
    J Cancer Res Ther; 2021 Jul; 17(3):790-796. PubMed ID: 34269315
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lynch-like syndrome: characterization and comparison with EPCAM deletion carriers.
    Kang SY; Park CK; Chang DK; Kim JW; Son HJ; Cho YB; Yun SH; Kim HC; Kwon M; Kim KM
    Int J Cancer; 2015 Apr; 136(7):1568-78. PubMed ID: 25110875
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mismatch repair protein status of non-neoplastic uterine and intestinal mucosa in patients with Lynch syndrome and double somatic mismatch repair protein mutations.
    Freitag CE; Chen W; Pearlman R; Hampel H; Stanich PP; Cosgrove CM; Konnick EQ; Pritchard CC; Frankel WL
    Hum Pathol; 2023 Jul; 137():1-9. PubMed ID: 37030500
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BRAF mutation analysis is a valid tool to implement in Lynch syndrome diagnosis in patients classified according to the Bethesda guidelines.
    Molinari F; Signoroni S; Lampis A; Bertan C; Perrone F; Sala P; Mondini P; Crippa S; Bertario L; Frattini M
    Tumori; 2014; 100(3):315-20. PubMed ID: 25076244
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Yield of routine molecular analyses in colorectal cancer patients ≤70 years to detect underlying Lynch syndrome.
    van Lier MG; Leenen CH; Wagner A; Ramsoekh D; Dubbink HJ; van den Ouweland AM; Westenend PJ; de Graaf EJ; Wolters LM; Vrijland WW; Kuipers EJ; van Leerdam ME; Steyerberg EW; Dinjens WN;
    J Pathol; 2012 Apr; 226(5):764-74. PubMed ID: 22081473
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mismatch repair deficiency concordance between primary colorectal cancer and corresponding metastasis.
    Haraldsdottir S; Roth R; Pearlman R; Hampel H; Arnold CA; Frankel WL
    Fam Cancer; 2016 Apr; 15(2):253-60. PubMed ID: 26666765
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rationale for evaluating breast cancers of Lynch syndrome patients for mismatch repair gene expression.
    Sorscher S
    Breast Cancer Res Treat; 2019 Nov; 178(2):469-471. PubMed ID: 31392519
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incorporation of somatic BRAF mutation testing into an algorithm for the investigation of hereditary non-polyposis colorectal cancer.
    Loughrey MB; Waring PM; Tan A; Trivett M; Kovalenko S; Beshay V; Young MA; McArthur G; Boussioutas A; Dobrovic A
    Fam Cancer; 2007; 6(3):301-10. PubMed ID: 17453358
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Compliance with mismatch repair testing in pT1 colorectal cancer diagnosed before the age of 70 years.
    Ykema BLM; Nagtegaal ID; Kuhlmann K; van Berkel AM; van Leerdam ME;
    Virchows Arch; 2021 Sep; 479(3):451-457. PubMed ID: 33718978
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.